• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

xerispharmaceuticals

Xeris enters collaboration with Merck

October 25, 2021 By Sean Whooley

Xeris Biopharma (NSDQ:XERS) announced today that it entered into a collaboration agreement with Merck (NYSE:MRK) for its XeriJect technology. Chicago-based Xeris’ collaboration with Merck includes an option to license the XeriJect suspension-based formulation technology for use with undisclosed monoclonal antibodies (mAbs) for engineering ultra-high concentration, ready-to-use formulations. Get the full story at our sister site, Drug Delivery Business […]

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceutical Tagged With: Merck, Xeris Biopharma, xerispharmaceuticals

FDA approves supplemental new drug application for Xeris’ hypoglycemia treatment

August 23, 2021 By Sean Whooley

Xeris Pharmaceuticals (NSDQ:XERS) announced today that the FDA approved its supplemental new drug application for the Gvoke kit. Chicago-based Xeris’ Gvoke (Ogluo in Europe) a ready-to-use pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia for people with diabetes ages 2 and above. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, xerispharmaceuticals

Xeris reaches payor coverage milestone for glucagon injection

August 13, 2021 By Sean Whooley

Xeris Pharmaceuticals (NSDQ:XERS) announced today that it achieved a milestone for the payor coverage of its Gvoke glucagon injection. Approximately 91% of Medicare patients, 88% of commercially insured patients and a growing number of Medicaid lives have unrestricted access to Gvoke, Xeris said in a news release. Get the full story at our sister site, Drug […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Medicare, Pharmaceutical Tagged With: xerispharmaceuticals

Xeris, Tetra Pharma enter $71M licensing agreement for glucagon injection

July 19, 2021 By Sean Whooley

Xeris Pharmaceuticals (NSDQ:XERS) announced today that it entered into an exclusive agreement with Tetris Pharma to commercialize Ogluo. Chicago-based Xeris designed Ogluo (Gvoke PFS and Gvoke HypoPen in the U.S.) to be a ready-to-use, pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia in adults, adolescents and children two years of age and older with diabetes mellitus. Get the […]

Filed Under: Business/Financial News, Contract Manufacturing, Diabetes, Drug-Device Combinations, Featured, Pharmaceutical Tagged With: Tetris Pharma, xerispharmaceuticals

Xeris Pharmaceuticals prices $27M offering

March 11, 2021 By Sean Whooley

Xeris Pharmaceuticals (NSDQ:XERS) announced today that it priced a registered direct offering of common stock at $27 million. Chicago-based Xeris is offering nearly 6.6 million shares of common stock to funds managed by Deerfield Management Company, which are existing investors in the company, according to a news release. Xeris develops technology platforms to enable ready-to-use, room-temperature […]

Filed Under: Business/Financial News, Drug Pumps, Drug-Device Combinations, Funding Roundup, Pharmaceutical Tagged With: xerispharmaceuticals

Xeris Pharmaceuticals launches autoinjector for severe hypoglycemia

July 1, 2020 By Danielle Kirsh

Xeris Pharmaceuticals today said it has launched its Gvoke HypoPen glucagon injection to treat severe hypoglycemia. The autoinjector is designed to treat severe hypoglycemia in adults and children with diabetes that are ages two years and older. The premixed autoinjector has no visible needle and has a reliable delivery method. According to the company, 99% […]

Filed Under: Diabetes Tagged With: xerispharmaceuticals

Xeris launches Ph2 trial of ready-to-use liquid glucagon

March 15, 2019 By Sarah Faulkner

Xeris Pharmaceuticals (NSDQ:XERS) said today that it dosed the first patients in a Phase II trial of its ready-to-use liquid glucagon in people with Type 1 diabetes. The Chicago-based company expects to report top-line data from the study in the second half of 2019. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceutical, Wall Street Beat Tagged With: xerispharmaceuticals

Xeris Pharmaceuticals touts data for glucagon auto-injector

November 14, 2018 By Sarah Faulkner

Xeris Pharmaceuticals (NSDQ:XERS) touted data this month for its ready-to-use glucagon auto-injector, highlighting the device’s efficacy and usability. The Chicago-based company’s rescue pen is under review for approval by the FDA as a treatment for severe hypoglycemia in people with diabetes. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceutical, Wall Street Beat Tagged With: xerispharmaceuticals

FDA to review Xeris’ glucagon rescue pen auto-injector

October 24, 2018 By Sarah Faulkner

Xeris Pharmaceuticals (NSDQ:XERS) said today that the FDA accepted its new drug application for a ready-to-use liquid glucagon rescue pen device. The company’s product is designed to treat severe hypoglycemia in people with diabetes. The FDA is slated to make a decision about Xeris’ pen by June 10, 2019. Get the full story at our sister […]

Filed Under: Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Wall Street Beat Tagged With: xerispharmaceuticals

Xeris Pharmaceuticals kicks off dual-hormone artificial pancreas trial

August 20, 2018 By Sarah Faulkner

Xeris Pharmaceuticals (NSDQ:XERS) said last week that it launched a Phase I trial of its ready-to-use liquid glucagon in a closed-loop, dual-hormone artificial pancreas system. Automated insulin delivery systems represent the latest advancement in diabetes management. But these technologies fall short of performing the tasks of a human pancreas – they deliver insulin, but they can’t […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: xerispharmaceuticals

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS